| Daver, Naval |
| Terminated | 1/2 | 24 | Europe, US | Lanraplenib, LANRA, Gilteritinib, XOSPATA® | Kronos Bio, Kronos Bio, Inc. | Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 04/24 | 04/24 | | |
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies |
|
|
| Recruiting | 1/2 | 181 | Europe, US | Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto® | Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML | 04/25 | 12/25 | | |
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 240 | Europe, US, RoW | Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine | Aptose Biosciences Inc. | Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia | 11/26 | 04/27 | | |
| Active, not recruiting | 1/2 | 179 | Europe, US | IMGN632 | AbbVie | Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm | 09/23 | 12/26 | | |
|
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 218 | Europe, US | Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto | AbbVie, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 04/26 | 04/26 | | |
| Recruiting | 1/2 | 70 | Europe, Canada, Japan, US, RoW | DSP-5336 | Sumitomo Pharma America, Inc. | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | 01/25 | 02/25 | | |
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) |
|
|
| Terminated | 1 | 37 | Europe, Japan, US, RoW | VOB560, S65487, MIK665, S64315 | Novartis Pharmaceuticals | Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) | 07/24 | 07/24 | | |
| Active, not recruiting | 1 | 160 | Europe, Canada, US | SL-172154, Azacitidine, Venetoclax | Shattuck Labs, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 11/24 | 11/24 | | |
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies |
|
|
| Recruiting | 1 | 36 | US | DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto | Kahr Medical | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 06/25 | 06/25 | | |
KT253-AL-101, NCT05775406: Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors |
|
|
| Completed | 1 | 52 | US | KT-253 | Kymera Therapeutics, Inc. | Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05986240: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML |
|
|
| Recruiting | 1 | 24 | US | Danvatirsen, AZD9150, Danvatirsen + Venetoclax, Venclexta | Montefiore Medical Center, M.D. Anderson Cancer Center, Flamingo Therapeutics NV | AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 10/25 | 07/28 | | |
NCT05155709 / 2021-001165-21: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. |
|
|
| Terminated | 1 | 14 | Europe, US, RoW | siremadlin, HDM201, venetoclax, azacitidine | Novartis Pharmaceuticals, Novartis Pharma AG | Acute Myeloid Leukemia | 04/24 | 04/24 | | |
| Platzbecker, Uwe |
| Active, not recruiting | 3 | 280 | Europe | Arsenic trioxide, ATO, Trisenox (R), As2O3, Idarubicin, IDA, Cytarabine, Ara-C, Tretinoin, all-trans retinoic acid, ATRA, Mitoxantrone, MTZ, Mercaptopurine, 6-Mercaptopurine, 6-MP, Methotrexate, MTX | Technische Universität Dresden, Gruppo Italiano Malattie EMatologiche dell'Adulto, Groupe Francophone des Myelodysplasies, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, German Federal Ministry of Education and Research, Teva Pharmaceuticals Europe | Acute Promyelocytic Leukemia | 01/25 | 01/25 | | |
NCT04712942: Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat |
|
|
| Completed | 2 | 14 | Europe | Pevonedistat, Azacitidine | University of Leipzig, Millennium Pharmaceuticals, Inc. | Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease | 01/23 | 01/23 | | |
| Recruiting | 2 | 28 | Europe | Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza® | Technische Universität Dresden, Merck Sharp & Dohme LLC | Acute Myeloid Leukemia | 12/25 | 12/26 | | |
IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy |
|
|
| Active, not recruiting | 2 | 46 | Europe, RoW | Imetelstat sodium, GRN163L | GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 02/25 | 06/26 | | |
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 |
|
|
| Terminated | 2 | 38 | Europe | CA-4948, Emavusertib | University of Leipzig, Curis, Inc. | Myelodysplastic Syndromes, Anemia | 07/24 | 07/24 | | |
| Recruiting | 2 | 41 | Europe | RVU120 (SEL120) | GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group | Low Risk Myelodysplastic Syndromes | 05/26 | 05/27 | | |
| Withdrawn | 2 | 108 | NA | Magrolimab, Hu5F9-G4, GS-4721, 7+3, Daunorubicine and Cytarabine, CPX-351, Vyxeos® | Uwe Platzbecker, Gilead Sciences | Acute Myeloid Leukemia, Myelodysplastic Neoplasm | 08/28 | 08/29 | | |
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 240 | Europe, US, RoW | Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine | Aptose Biosciences Inc. | Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia | 11/26 | 04/27 | | |
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 218 | Europe, US | Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto | AbbVie, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 04/26 | 04/26 | | |
| Recruiting | 1/2 | 366 | Europe, US, RoW | Emavusertib, CA-4948, Venetoclax | Curis, Inc., Curis, Inc | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | 04/26 | 04/26 | | |
GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome |
|
|
| Completed | 1 | 44 | Europe, RoW | SLN124, Placebo | Silence Therapeutics plc | Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome | 05/23 | 05/23 | | |
| Stelljes, Matthias |
| Recruiting | 3 | 210 | Europe | MC0518, BAT | medac GmbH | Steroid-refractory Acute Graft-versus-host Disease | 08/27 | 08/30 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 1/2 | 48 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory | 12/24 | 12/24 | | |
| Berg, Thomas |
| Recruiting | 3 | 380 | Europe, US | SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT | Grifols Therapeutics LLC, Instituto Grifols, S.A. | Acute-On-Chronic Liver Failure | 10/26 | 10/26 | | |
DHELIVER, NCT04229901: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) |
|
|
| Terminated | 2 | 133 | Europe, RoW | HepaStem, Placebo | Cellaion SA | Acute on Chronic Liver Failure | 05/24 | 05/24 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
| Recruiting | N/A | 1000 | Europe | Physician's choice according to patient's needs. | iOMEDICO AG | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | 12/26 | 12/26 | | |
NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry) |
|
|
| Recruiting | N/A | 500 | Europe, RoW | | Orphalan, Ergomed | Wilson's Disease | 12/27 | 12/27 | | |
| Michalski, Dominik |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
| Lordick, Florian |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 36 | Europe | Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo | Esophagogastric Adenocarcinoma | 12/27 | 12/27 | | |
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 1/2 | 56 | Europe | Sacituzumab govitecan, Trodelvy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences | Esophagogastric Adenocarcinoma | 02/27 | 03/27 | | |
| Recruiting | N/A | 900 | Europe | Routine care as per site standard | iOMEDICO AG | Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 12/24 | | |
| Scheinert, Dierk |
NCT03751527: ZENFlex-Registry to Evaluate the Outcome of Bare Metal Stent-assisted Angioplasty |
|
|
| Recruiting | N/A | 200 | Europe | ZENFLEX peripheral stent system | Zhejiang Zylox Medical Device Co., Ltd. | Atherosclerosis of Femoral Artery | 12/22 | 12/23 | | |
| Active, not recruiting | N/A | 70 | Europe | Solaris Vascular Stent Graft | Dr. Sabrina Overhagen, FCRE (Foundation for Cardiovascular Research and Education), Scitech Produtos Medicos Ltda | Peripheral Arterial Disease, Iliac Artery Stenosis, Common Femoral Artery Stenosis | 11/24 | 12/24 | | |
| Recruiting | N/A | 300 | Europe, US, RoW | SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Superficial Femoral Artery Stenosis | 08/25 | 12/29 | | |
STRIDE II, NCT06747117: A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System |
|
|
| Not yet recruiting | N/A | 300 | NA | Indigo Aspiration System | Penumbra Inc. | Lower Extremity Acute Limb Ischemia, LE ALI | 06/28 | 01/29 | | |
| Recruiting | N/A | 204 | Europe | ESAR treatment: Endograft + Heli-FX Endoanchor, FEVAR treatment : Fenestrated endograft | FCRE (Foundation for Cardiovascular Research and Education), Medtronic | Aortic Aneurysm, Abdominal | 06/26 | 06/28 | | |
LIMES, NCT04772300: Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 230 | Europe | Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter, Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA) | Jena University Hospital, Concept Medical Inc., Vascuscience, CoreLab Black Forest, Center for Clinical Studies, University Hospital Jena | Peripheral Artery Disease | 12/27 | 09/28 | | |
| Kimberger, Oliver |
| Recruiting | N/A | 100 | Europe | Checklist for evaluation of reversible causes, Venipuncture for toxicological screening, Point-of-Care blood gas analysis, Point-of-Care saliva toxicological screen, Point-of-care ultrasound | Medical University of Vienna, Seibersdorf Labor GmbH, Ludwig Boltzmann Institute for Digital Health and Prevention | Out-Of-Hospital Cardiac Arrest, Cardiopulmonary Arrest | 04/25 | 12/25 | | |
NCT05953363: Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories. |
|
|
| Completed | N/A | 161 | Europe | BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes | Becton, Dickinson and Company | Anesthesia, Analgesia | 05/24 | 06/24 | | |
| Kim, Young Woo |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 496 | RoW | Neu2000KWL group, Placebo group | GNT Pharma | Ischemic Stroke | 06/24 | 01/25 | | |
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
|
|
| Suspended | 3 | 220 | Europe, Canada, US, RoW | SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin | Scynexis, Inc., SCYNEXIS, Inc. | Candidiasis, Invasive, Candidemia | 06/24 | 08/24 | | |
| Recruiting | 3 | 300 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Weight Gain | 05/27 | 06/27 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 02/26 | 02/27 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 |
|
|
| Recruiting | 2/3 | 600 | Canada, US, RoW | Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan | Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT) | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer | 08/27 | 02/28 | | |
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment |
|
|
| Recruiting | 2 | 38 | RoW | Avelumab and Gemcitabine | Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp. | Leiomyosarcoma Metastatic | 12/21 | 12/22 | | |
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers |
|
|
| Completed | 2 | 79 | Europe, Canada, US, RoW | Mirvetuximab soravtansine, MIRV, IMGN853 | AbbVie | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 01/24 | 12/24 | | |
|
|
|
|
NCT06723405: Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 60 | RoW | EVO301, Placebo | Evommune, Inc. | Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis | 01/26 | 01/26 | | |
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation |
|
|
| Recruiting | 2 | 40 | US, RoW | ABN401 | Abion Inc | Advanced Solid Tumors | 04/25 | 08/25 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 250 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
| Recruiting | N/A | 12000 | RoW | | Seoul National University Hospital, Astellas Pharma Inc | Kidney Transplant Rejection | 07/24 | 08/24 | | |
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma |
|
|
| Approved for marketing | N/A | | Europe, Canada, US, RoW | Olaratumab, LY3012207 | Eli Lilly and Company | Soft Tissue Sarcoma | | | | |
OBE-KMT22-01, NCT06250608: Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients. |
|
|
| Recruiting | N/A | 35 | RoW | Pulse oximeter, NIRSITX | OBELAB, Inc., Helptrial Inc. | Acute Ischemic Stroke Patients | 12/25 | 12/25 | | |
NCT05933005: Intervention Utilizing a Computerized Cognitive Rehabilitation Program (D-kit/EF1) |
|
|
| Recruiting | N/A | 80 | US | D-kit/EF1, Sham group program | University of California, San Francisco, DoBrain Inc. | Mild Intellectual Disability, Borderline Intellectual Functioning | 08/24 | 10/24 | | |
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial |
|
|
| Recruiting | N/A | 9 | RoW | ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell | Anterogen Co., Ltd. | Crohn Disease | 12/26 | 12/26 | | |
| Laufs, Ulrich |
| Active, not recruiting | 3 | 75 | Europe, Canada, Japan, US, RoW | Plozasiran, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Familial Chylomicronemia | 04/24 | 04/26 | | |
| Kuhnt, Thomas |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
| Al-Batran, Salah |
NCT05101629 / 2021-000355-40: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy |
|
|
| Active, not recruiting | 2 | 32 | Europe | Pembrolizumab, Keytruda, Lenvatinib Capsules, Lenvima | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel, Merck Sharp & Dohme LLC | Hepatocellular Carcinoma | 01/25 | 12/25 | | |
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy |
|
|
| Not yet recruiting | 2 | 126 | Europe | bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich | Metastatic Gastro-esophageal Adenocarcinoma | 09/27 | 03/28 | | |
NCT05504720 / 2021-006512-87: Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 31 | Europe | Pembrolizumab, Keytruda, Trastuzumab, Ontruzant, FLOT | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Merck Sharp & Dohme LLC, Organon Healthcare GmbH | Esophagogastric Adenocarcinoma | 10/27 | 12/27 | | |
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 36 | Europe | Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo | Esophagogastric Adenocarcinoma | 12/27 | 12/27 | | |
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 1/2 | 56 | Europe | Sacituzumab govitecan, Trodelvy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences | Esophagogastric Adenocarcinoma | 02/27 | 03/27 | | |
| Hacker, Ulrich |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
